MINI FUTURE SHORT - ELI LILLY & CO | Real-time Euronext Paris 04:57:12 2024-07-17 am EDT | ||
| 2.152 EUR | +39.38% |
|
| Current month | -31.98% | ||
| 1 month | -44.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 2.152 | +39.38% |
| 24-07-16 | 1.544 | +5.39% |
| 24-07-15 | 1.465 | -10.23% |
| 24-07-12 | 1.632 | -16.61% |
| 24-07-11 | 1.957 | +20.06% |
Real-time Euronext Paris
Last update July 17, 2024 at 04:57 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| US5OB | |
| ISIN | NLBNPNL2SJH8 |
| Date issued | 2024-06-04 |
| Strike | 1,033 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 3.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.854 € |
|---|---|
| Lowest since issue | 1.228 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
893.8
USD
Spread / Average Target
-5.08%
- Stock Market
- Certificates
- US5OB Certificat
